These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36114420)

  • 1. Autoprocessing and oxyanion loop reorganization upon GC373 and nirmatrelvir binding of monomeric SARS-CoV-2 main protease catalytic domain.
    Nashed NT; Kneller DW; Coates L; Ghirlando R; Aniana A; Kovalevsky A; Louis JM
    Commun Biol; 2022 Sep; 5(1):976. PubMed ID: 36114420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unmasking the Conformational Stability and Inhibitor Binding to SARS-CoV-2 Main Protease Active Site Mutants and Miniprecursor.
    Kovalevsky A; Coates L; Kneller DW; Ghirlando R; Aniana A; Nashed NT; Louis JM
    J Mol Biol; 2022 Dec; 434(24):167876. PubMed ID: 36334779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stabilization of the Dimeric State of SARS-CoV-2 Main Protease by GC376 and Nirmatrelvir.
    Paciaroni A; Libera V; Ripanti F; Orecchini A; Petrillo C; Francisci D; Schiaroli E; Sabbatini S; Gidari A; Bianconi E; Macchiarulo A; Hussain R; Silvestrini L; Moretti P; Belhaj N; Vercelli M; Roque Y; Mariani P; Comez L; Spinozzi F
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of the monomer-dimer equilibrium and catalytic activity of SARS-CoV-2 main protease by a transition-state analog inhibitor.
    Nashed NT; Aniana A; Ghirlando R; Chiliveri SC; Louis JM
    Commun Biol; 2022 Mar; 5(1):160. PubMed ID: 35233052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2.
    Zhao Y; Zhu Y; Liu X; Jin Z; Duan Y; Zhang Q; Wu C; Feng L; Du X; Zhao J; Shao M; Zhang B; Yang X; Wu L; Ji X; Guddat LW; Yang K; Rao Z; Yang H
    Proc Natl Acad Sci U S A; 2022 Apr; 119(16):e2117142119. PubMed ID: 35380892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using serpins cysteine protease cross-specificity to possibly trap SARS-CoV-2 Mpro with reactive center loop chimera.
    Jairajpuri MA; Ansari S
    Clin Sci (Lond); 2020 Sep; 134(17):2235-2241. PubMed ID: 32869854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An extended conformation of SARS-CoV-2 main protease reveals allosteric targets.
    Sun Z; Wang L; Li X; Fan C; Xu J; Shi Z; Qiao H; Lan Z; Zhang X; Li L; Zhou X; Geng Y
    Proc Natl Acad Sci U S A; 2022 Apr; 119(15):e2120913119. PubMed ID: 35324337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery.
    Ray AK; Sen Gupta PS; Panda SK; Biswal S; Bhattacharya U; Rana MK
    Comput Biol Med; 2022 Mar; 142():105183. PubMed ID: 34986429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unusual zwitterionic catalytic site of SARS-CoV-2 main protease revealed by neutron crystallography.
    Kneller DW; Phillips G; Weiss KL; Pant S; Zhang Q; O'Neill HM; Coates L; Kovalevsky A
    J Biol Chem; 2020 Dec; 295(50):17365-17373. PubMed ID: 33060199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allosteric Regulation of 3CL Protease of SARS-CoV-2 and SARS-CoV Observed in the Crystal Structure Ensemble.
    Kidera A; Moritsugu K; Ekimoto T; Ikeguchi M
    J Mol Biol; 2021 Dec; 433(24):167324. PubMed ID: 34717972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic Surveillance of SARS-CoV-2 M
    Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
    mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new inactive conformation of SARS-CoV-2 main protease.
    Fornasier E; Macchia ML; Giachin G; Sosic A; Pavan M; Sturlese M; Salata C; Moro S; Gatto B; Bellanda M; Battistutta R
    Acta Crystallogr D Struct Biol; 2022 Mar; 78(Pt 3):363-378. PubMed ID: 35234150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recognition of Divergent Viral Substrates by the SARS-CoV-2 Main Protease.
    MacDonald EA; Frey G; Namchuk MN; Harrison SC; Hinshaw SM; Windsor IW
    ACS Infect Dis; 2021 Sep; 7(9):2591-2595. PubMed ID: 34437808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural differences in 3C-like protease (Mpro) from SARS-CoV and SARS-CoV-2: molecular insights revealed by Molecular Dynamics Simulations.
    Parmar M; Thumar R; Patel B; Athar M; Jha PC; Patel D
    Struct Chem; 2022 Nov; ():1-18. PubMed ID: 36467259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dimerization Tendency of 3CLpros of Human Coronaviruses Based on the X-ray Crystal Structure of the Catalytic Domain of SARS-CoV-2 3CLpro.
    Jo S; Kim HY; Shin DH; Kim MS
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-dimensional domain swapping as a mechanism to lock the active conformation in a super-active octamer of SARS-CoV main protease.
    Zhang S; Zhong N; Xue F; Kang X; Ren X; Chen J; Jin C; Lou Z; Xia B
    Protein Cell; 2010 Apr; 1(4):371-383. PubMed ID: 21203949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Identifying SARS-CoV-2 main protease inhibitors by a novel sandwich-like fluorescence polarization screening assay].
    Yan H; Yan G; Qi H; Liu Z; Liu X; Liu X; Li N; Chen Y
    Sheng Wu Gong Cheng Xue Bao; 2022 Jun; 38(6):2352-2364. PubMed ID: 35786485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site.
    Lee J; Worrall LJ; Vuckovic M; Rosell FI; Gentile F; Ton AT; Caveney NA; Ban F; Cherkasov A; Paetzel M; Strynadka NCJ
    Nat Commun; 2020 Nov; 11(1):5877. PubMed ID: 33208735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of potential plant-based inhibitor against viral proteases of SARS-CoV-2 through molecular docking, MM-PBSA binding energy calculations and molecular dynamics simulation.
    Gogoi B; Chowdhury P; Goswami N; Gogoi N; Naiya T; Chetia P; Mahanta S; Chetia D; Tanti B; Borah P; Handique PJ
    Mol Divers; 2021 Aug; 25(3):1963-1977. PubMed ID: 33856591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.
    Amin SA; Banerjee S; Ghosh K; Gayen S; Jha T
    Bioorg Med Chem; 2021 Jan; 29():115860. PubMed ID: 33191083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.